Zoledronic Acid

Catalog No.S1314 Synonyms: Zoledronate, CGP-4244

Zoledronic Acid  Chemical Structure

Molecular Weight(MW): 272.09

Zoledronic acid (ZA), a potent osteoclast inhibitor, induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

2 Customer Reviews

  • Isolation of cd T cells. PBMCs were cultured in the presence of 400 nM ZA and 200 IU/ml IL-2 over 10 days. cd T cells were isolated by negative MACS isolation. Flow cytometric analysis revealed co-expression of CD3 and TCRcd on over 99% of cells of the flow through fraction (A). The T cells expressed the TCRVd2 chain (B) and the CD56 protein (C).

    Liver Int 2013 33(1), 127-36. Zoledronic Acid purchased from Selleck.

    Quantification (C) of SA-β-gal+ SMCs after sustained 100nM ADP treatment for 48hr with or without Ras inhibitor zoledronic acid (ZA) (n=4 in each group). #p<0.05, ##p<0.01 compared with control, *p<0.05 compared with P2ry12+/+ADP. (D) Incidence of TAAD formation and rupture after BAPN administration with or without ZA. (E) Elastin degradation grades of mice aortas after BAPN administration with or without ZA. (F) Representative H&E staining of thoracic aorta and progression of thoracic aorta diameter of mice aortas after BAPN administration with or without ZA (n=8 in both group). (G) Representative images and quantification of SA-β-gal (blue) staining in mouse aorta after BAPN administration with or without ZA (n=4 in both group); arrow, location of SA-β-gal+ area. (H) Immunostaining and quantification of p-ERK and p-p38 in mouse aorta with or without ZA (n=4 in both group). Data are meanSD from three experiments.*p<0.05, compared with no ZA.

    J Mol Cell Cardiol, 2016, 99:76-86.. Zoledronic Acid purchased from Selleck.

Purity & Quality Control

Choose Selective Rho Inhibitors

Biological Activity

Description Zoledronic acid (ZA), a potent osteoclast inhibitor, induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho.
Targets
Rho [1]
(Cell-free assay)
In vitro

Zoledronic acid (10 µM and 100 µM) causes a significant reduction in the proportions of MCF-7 cells (49.54% and 23.55% of control, respectively) (P < 0.05). Zoledronic acid has little effect on MDA-MB-231 cells at concentrations of 0.1–10 µM, whereas the 100 µM concentration results in a significant reduction in cell number. Zoledronic acid (100 µM) results in a 63.5% reduction in MCF-7 cell number at 72 hours and an 87.1% reduction at 96 hours. Zoledronic acid (10 µM) results in a greater than 4-fold increase in MCF-7 cell apoptosis whereas the 100 µM concentration induces a 6-fold increase in the proportion of apoptotic cells. Zoledronic acid (10 µM) and paclitaxel (2 µM) results in a 5-fold increase in apoptosis (774.8% of control) compared to zoledronic acid alone (155.71%) and a 4-fold increase compared to paclitaxel alone (189.68%). Zoledronic acid-induced apoptosis of MCF-7 breast cancer cells can be inhibited by addition of intermediates of the mevalonate pathway, which is consistent with observations in osteoclasts, macrophages and myeloma cells. [1] Zoledronic acid enhances OPG gene expression and protein secretion by human osteoblasts (hOB) in a dose-dependent fashion with a maximum effect at 10 nM after 72 hours, consistent with the higher biological potency of Zoledronic acid. Zoledronic acid prevents the inhibitory effects of the glucocorticoid dexamethasone on OPG mRNA and protein production in human osteoblasts. Zoledronic acid induces type I collagen secretion and alkaline phosphatase activity by 2- and 4-fold, respectively, in human osteoblasts. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human foreskin fibroblast monolayer cells (HFF cells) NHvIdGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEC4NJhKdiC4aYTyc{BqdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDD0bIUh\3Kxd4ToJI9nKFSxeH;wcIF{dWFiZ3;u[IlqKGmwIHj1cYFvKG[xcnXzb4lvKG[rYoLvZoxie3RibX;uc4xigWW{IHPlcIx{KCiKRl[gZ4VtdHNrLDDJR|UxRTBwN{mg{txO M4L1bFE2QDV5MUG5
human Gamma delta T cells MVHGeY5kfGmxbjDhd5NigQ>? Mlj5SYZn\WO2aY\lJINwdmOnboTyZZRqd25iYXfhbY5{fCCqdX3hckBI[W2vYTDk[Yx1[SCWIHPlcIx{NCCHQ{WwQVUvPCEQvF2= NH\2OVQyPTh{OEizOC=>
mouse J774 cells M3XIbGN6fG:2b4jpZ:Kh[XO|YYm= MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDKO|c1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSxiSVO1NF04NjhizszN MmK3NlQ5OTN5NEK=
human RPMI8226 cells NV7ufWJVS3m2b4TvfIlkyqCjc4PhfS=> Ml2wO|IhcA>? M{jDPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJRVUl6MkK2JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFXDOVA:OTFizszN M{jDTVI{QTl6OUKx
human NCI-H460 cell NWrMOJh{WHKxbHnm[ZJifGmxbjDhd5NigQ>? MkP2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsJIxqdmViYomgUXRVKGG|c3H5MEBKSzVyPUGxMlch|ryP NY[2PYMyOTZ7N{C0NFU>
human SF-268 cell MUXQdo9tcW[ncnH0bY9vKGG|c3H5 NWPhU|lqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTSk0zPjhiY3XscEBtcW6nIHL5JG1VXCCjc4PhfUwhUUN3ME2xOE4{KM7:TR?= NEX0bFEyPjl5MESwOS=>
human MCF7 cells MXfQdo9tcW[ncnH0bY9vKGG|c3H5 MoK2O|IhcA>? MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0zOyEQvF2= NUf6UHhEOjR7MkizPVk>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
ALDH1 / Oct4 / Nanog / Sox2 / CD49f ; 

PubMed: 30791957     


Western blot analysis of ALDH1, Sox2, CD49f, Nanog, and Oct4 in cervical cancer cells derived CSCs treated or not with zoledronic acid (10, 20, and 30 μM).

N-cadherin / E-cadherin / Vimentin ; 

PubMed: 30791957     


Western blot analysis of E-cadherin, N-cadherin, and Vimentin in cervical cancer cells derived CSCs treated or not with zoledronic acid (10, 20, and 30 μM).

30791957
Growth inhibition assay
Cell viability; 

PubMed: 30791957     


Zoledronic acid inhibits the proliferation of cervical cancer cells derived CSCs in vitro. Parental HeLa, SiHa, and CaSki cells as well as their derived CSCs were seeded in 96-well plates and treated with zoledronic acid at different concentrations for 1–5 days. Cell viability was determined by the modified MTT assay. OD values of each treated group were compared with that of the control at the same time point. Control vs. 5, 10, 20, 40, and 80 μM of zoledronic acid: * P < 0.05, ** P < 0.01. Results are shown as mean values ± SD of independent experiments performed in triplicate.

30791957
In vivo Zoledronic acid (120 mg/kg, s.c.) prevents the formation of lesions, prevents cancellous bone loss and loss of bone mineral density, and reduces osteoclast perimeter in 5T2MM-bearing mice. Zoledronic acid (120 mg/kg, s.c.) also decreases paraprotein concentration, decreases tumor burden, and reduces angiogenesis in 5T2MM-bearing mice. [3]

Protocol

Solubility (25°C)

In vitro 0.1M NaOH (aq) 40 mg/mL (147.01 mM)
DMSO 0.004 mg/mL (0.01 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 272.09
Formula

C5H10N2O7P2

CAS No. 118072-93-8
Storage powder
in solvent
Synonyms Zoledronate, CGP-4244

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04034199 Not yet recruiting Drug: Denosumab|Drug: Zoledronic Acid Idiopathic Inflammatory Myopathies|Osteoporosis Osteopenia Kwong Wah Hospital|Tung Wah Group of Hospitals August 15 2019 Phase 3
NCT03862833 Recruiting Drug: IL2|Drug: Zoledronic Acid Hematopoietic Stem Cell Transplantation Nantes University Hospital May 7 2019 Phase 1
NCT03301285 Completed Drug: Zoledronic Acid Multiple Disability|Osteoporosis Central Hospital Nancy France January 1 2017 --
NCT02632903 Withdrawn Drug: Zoledronic acid Osteoporosis|Osteonecrosis|Acute Lymphoblastic Leukemia Children''s Hospital of Eastern Ontario October 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo studies?

  • Answer:

    Please dissolve this compound directly to 30% PEG400+0.5% Tween80+5% Propylene glycol.

Rho Signaling Pathway Map

Tags: buy Zoledronic Acid | Zoledronic Acid ic50 | Zoledronic Acid price | Zoledronic Acid cost | Zoledronic Acid solubility dmso | Zoledronic Acid purchase | Zoledronic Acid manufacturer | Zoledronic Acid research buy | Zoledronic Acid order | Zoledronic Acid mouse | Zoledronic Acid chemical structure | Zoledronic Acid mw | Zoledronic Acid molecular weight | Zoledronic Acid datasheet | Zoledronic Acid supplier | Zoledronic Acid in vitro | Zoledronic Acid cell line | Zoledronic Acid concentration | Zoledronic Acid nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID